2006-10-01
Growth hormone receptor antagonists
Publication
Publication
Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships , Volume 83 - Issue 3-4 p. 264- 268
The currently available long-acting somatostatin analogs normalize serum growth hormone (GH) levels and insulin-like growth factor-I levels in approximately 60% of patients with acromegaly. The recently introduced GH receptor antagonist, pegvisomant, is able to normalize insulin-like growth factor-I levels in virtually all acromegalic subjects. Although no correlation between increased GH concentrations and tumor size has been found, long-term safety studies are still in progress. Also, pegvisomant monotherapy is administered once daily and is very costly. Combined treatment of a somatostatin analog with pegvisomant appears to be an effective and rational approach. Copyright
| Additional Metadata | |
|---|---|
| , , | |
| doi.org/10.1159/000095537, hdl.handle.net/1765/65965 | |
| Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships | |
| Organisation | Department of Internal Medicine |
|
van der Lely, A.-J., & Kopchick, J. (2006). Growth hormone receptor antagonists. In Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships (Vol. 83, pp. 264–268). doi:10.1159/000095537 |
|